Drug Profile
Research programme: immunoconjugated micelles - Eisai/Nanocarrier
Alternative Names: NC 6201Latest Information Update: 01 Sep 2023
Price :
$50
*
At a glance
- Originator Eisai Co Ltd; NanoCarrier
- Developer NanoCarrier
- Class Amides; Antineoplastics; Dipeptides; Immunoconjugates; Piperidines
- Mechanism of Action Immunomodulators; Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 01 Sep 2023 Discontinued - Preclinical for Cancer in Japan (IV) (before September 2023) (Eisai Pipeline, September 2023)
- 28 May 2020 No recent reports of development identified for preclinical development in Cancer in Japan (IV)
- 14 Apr 2016 Preclinical trials in Cancer in Japan (IV)